Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0006142 (
breast cancer
)
160,383
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Long-term survival, the prognostic effects of race, age, tumor size, number of positive nodes, and presence of grave signs (fixation,
peau d'orange
/edema, dimpling/retraction, satellite nodules, and ulceration) in this distribution of estrogen receptors (ERs) and progesterone receptors (PRs) were studied in 2480 patients (1815 blacks, 665 whites) diagnosed with localized or regional
breast cancer
at Charity Hospital of Louisiana at New Orleans (CHNO) from 1948 to 1985 and followed up in the CHNO Tumor Registry.
Breast cancer
-specific survival rates were 57%, 45%, 41%, 39%, 38%, and 35% at 5, 10, 15, 20, 25, and 30 years, respectively. Size of tumor, clinical status of nodes, and degree of fixation were important prognostic clinical factors, and number of nodes was an important pathologic factor with no additional value of the "grave signs." Size and fixation were related. Independent of size, clinical and pathologic status and fixation were related. ER was related to age and PR was related to number of nodes. The excess mortality from
breast cancer
at later intervals from diagnoses was small compared with mortality from other causes. Some, but not all, clinical findings were important prognostic indicators. ER and PR were related to some variables with unclear meaning.
...
PMID:Charity Hospital experience with long-term survival and prognostic factors in patients with breast cancer with localized or regional disease. 337 67
Between 1948 and 1981, 1230 patients were diagnosed as having regional (skin, muscle, or chest wall attachment)
breast cancer
, and long-term survival was studied. In all patients, overall survival was 33% at 5 years, 19% at 10 years, and 9% at 20 years. Significant excess mortality due to
breast cancer
was observed throughout the 20-year follow-up period (P less than 0.002). The risk of
breast cancer
was highest in the 5-year period following diagnosis, and declined steadily from that time. Additionally, 308 patients diagnosed since 1968 were studied for the effect of prognostic factors. Clinical status of nodes (positive or negative) and presence or absence of
peau d'orange
were found to be significant prognostic factors in those patients. In those receiving radical surgery, the number of nodes and presence or absence of
peau d'orange
were found to be of prognostic significance. No effect of race, age, year of diagnosis, site of attachment, type of fixation, ulceration, edema, size of tumor, satellite nodules, or dimpling retraction on breast-cancer-specific survival was observed when the nodal status and
peau d'orange
were controlled. These data demonstrate that mortality in regional
breast cancer
is significant and is highly dependent on
peau d'orange
and nodal status.
...
PMID:Long-term survival and prognostic factors in patients with regional breast cancer (skin, muscle, and/or chest wall attachment). 397 9
Sarcoidosis is a multisystemic disease that may involve the breast parenchyma and can be confused with benign or malignant tumors. A recent case of sarcoidosis of the breast treated in our institution prompted us to review the world literature on the topic. From 1921 to 1997, 45 cases relating to sarcoidosis of the breast were reported; 10 of these cases were excluded from our review because of the lack of histological proof of sarcoidosis. The data were organized according to clinical presentation, diagnostic studies, treatment plan, and follow-up care. The mean age at presentation was 47 years (range 20-72 years) and all patients were female. Seven patients (20%) had a breast mass as primary presentation of sarcoidosis without any clinical evidence of systemic sarcoidosis. Thirty-one patients (89%) presented with a self-detected mass and three patients (8%) demonstrated skin dimpling and
peau d'orange
appearance mimicking cancer. The size of the breast lesions ranged from 0.25 to 5 cm in diameter. One patient presented with bilateral breast lesions and one with more than one lesion in the same affected breast. A single breast mass was found in the rest of the patients. Of the seven patients evaluated by mammography, only one revealed changes suspicious for malignancy. Fine-needle aspiration was used only in four cases; the results of two were compatible with sarcoidosis and two required an excisional biopsy as a result of inconclusive results. Seventeen cases reported excisional biopsy as the diagnostic procedure. In 11 patients the type of biopsy was not stated. In two cases of radical mastectomies for breast adenocarcinoma, sarcoidosis was an incidental finding, either in the remaining breast tissue or in the axillary nodes. One patient underwent a partial mastectomy revealing sarcoidosis as the definitive diagnosis. Ultrasound was used in two cases; one revealed a suspicious lesion and one was inconclusive. Although sarcoidosis of the breast constitutes a rare entity it should be considered in the differential diagnosis of
breast cancer
even in patients without clinical evidence of systemic sarcoidosis. These patients should undergo a biopsy to rule out malignancy because clinical findings, mammography, and ultrasound results can be misleading or inconclusive.
...
PMID:Sarcoidosis of the breast: implications for the general surgeon. 1114 86
Postoperative radiotherapy (RT) forms an intrinsic part of breast conservation therapy, substantially reducing the risk of breast relapse. It is given 4-6 weeks postoperatively using medial and lateral beams to achieve a near homogeneous dose to the breast while minimising the dose to adjacent structures. Typically, a dose of 40 Gy in 15 daily fractions over three weeks or 50 Gy in 25 fractions over five weeks is given, with a boost of 10 Gy using low energy electrons or superficial X-rays. RT is delivered to the chest wall after mastectomy in patients with large tumours (> 5 cm), close surgical margins, or significant axillary node involvement and may result in an additional 10% survival benefit. Early complications of RT include tiredness, skin erythema and moist desquamation. Late reactions, breast fibrosis, telangiectases and
peau d'orange
are reduced if more treatment fractions are given. Lung irradiation is minimised by careful treatment planning and < 1% of patients experience radiation pneumonitis or pulmonary fibrosis. Patients with locally advanced
breast cancer
may be offered a combination of systemic therapy, endocrine, chemotherapy and radical RT. Preoperative systemic and radiation therapy reduces the mastectomy rate but at present does not improve survival. Those who are unfit for radical treatment and have large ulcerating or fixed cancers are offered either endocrine or cytotoxic therapy, depending upon the oestrogen receptor status, followed by RT, which is unlikely to cure but may achieve local control for a variable duration. RT forms part of the multidisciplinary approach to palliative treatment for metastatic disease. Bone metastases occur in 75% of women with metastatic disease and RT provides effective pain relief and reducing risk of pathological fractures. Patients with brain metastases need high-dose steroids followed by cranial RT.
...
PMID:Radiotherapy for early and advanced breast cancer. 1177 Mar 58
Inflammatory breast cancer (IBC) is the most aggressive form of locally advanced
breast cancer
. It can be diagnosed based on a clinical or pathologic basis. We evaluated the usefulness of (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET) scans for diagnosing and staging IBC. We retrospectively reviewed the medical records of seven consecutive patients with IBC who underwent FDG-PET scanning for the initial staging. Four patients had follow-up PET scans after chemotherapy. All seven patients presented with diffuse breast enlargement, redness, and
peau d'orange
for 1 to 5 months' duration. In addition, four patients had a palpable breast mass, and three had axillary lymph node enlargement. Mammography showed diffuse, increased parenchymal density and skin thickening in 85% and parenchymal distortion in 43%. There was no evidence of distant metastasis on computed tomography of the chest or abdomen. Pathologic examination of breast biopsy specimens showed infiltrating ductal carcinoma in six patients, and one had lobular carcinoma. All patients had prechemotherapy whole-body PET scans that showed diffuse FDG uptake in the breast with superimposed intense foci in the primary tumor. Furthermore, there was skin enhancement in 100%, axillary lymph node in 85%, and skeletal metastases in 14% of the patients, confirmed by bone scintigraphy. Postchemotherapy FDG-PET scans performed in four patients showed response in the primary tumor, axillary lymph nodes, and skeletal metastases. The FDG-PET scan is thus useful for displaying the pattern of FDG breast uptake that reflects the extent of the pathologic involvement in IBC (i.e., diffuse breast involvement and dermal lymphatic spread). It can also detect the presence of lymph node and skeletal metastases, demarcating the extent of the disease locally as well as distally.
...
PMID:18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer. 1291 70
Occult
breast cancer
presenting with axillary lymph node metastases is uncommon, and inflammatory breast cancer (IBC), as a subtype, is quite rare. Here we describe a case of IBC, which arose as an unknown primary carcinoma; the patient presented with axillary lymph node metastasis, and was successfully treated with trastuzumab and vinorelbine. Specifically, a 55-year-old woman presented with right axillary lymphadenopathy. Although she underwent various examinations, the primary site of the disease was not revealed. Axillary lymph node dissection was performed, and the lesion was diagnosed as a poorly differentiated adenocarcinoma. The patient chose to be treated by alternative medicine. About 6 months later, she was referred to our hospital, due to marked bilateral neck and axillary lymph node swelling. She presented with diffuse right breast enlargement, redness, and
peau d'orange
. Computed tomography (CT) of the breast showed skin thickening and swelling of the right breast.F-18 Fluorodeoxyglucose positron emission tomography (FDG-PET) showed FDG uptake in the right breast. The patient was clinically diagnosed with IBC. Because overexpression of the human epidermal growth factor receptor 2 (HER2) was found in the specimen from her right axillary lymph node, she was treated with trastuzumab and vinorelbine. Two months after the start of chemotherapy, CT revealed a complete response in the lymph nodes, and the skin thickening and parenchymal edema of the right breast had improved. FDG-PET was also performed at this time, and revealed no FDG uptake in either the right breast or the lymph nodes.
...
PMID:Unknown primary carcinoma, diagnosed as inflammatory breast cancer,and successfully treated with trastuzumab and vinorelbine. 1613 77
Inflammatory breast cancer (IBC) is a rare and aggressive form of
breast cancer
with unknown etiology and generally poor outcome. It is characterized by diffuse edema (
peau d'orange
) and redness (erythema), although either the disease itself or case definitions have varied over time and place, confounding temporal trends and geographic variations. In this review, we discuss case definitions for IBC and its clinical characteristics; describe its geographic variation, age and racial distribution, incidence and survival patterns, and summarize the very limited information on its epidemiologic risk factors. We also incorporate emerging data from the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Program.
...
PMID:Epidemiology of inflammatory breast cancer (IBC). 1673 83
The intact primary in patients diagnosed with Stage IV
breast cancer
is generally reserved for palliative indications. Haagensen and Stout's 1943 criteria of inoperability for carcinoma of the breast, including tumor fixation to the chest wall, ulceration, and
peau d'orange
, hold true. Surgery alone is unlikely to prolong life in such patients. Improvements in
breast cancer
screening and awareness mean fewer patients having inoperable
breast cancer
. The current problem is that imagining studies reveal some patients to have oligometastatic disease with an intact primary. This article considers surgical treatment as part of multimodal Stage IV
breast cancer
treatment for such patients. Several challenges to previous dogma to never operate on Stage IV
breast cancer
patients except with palliative intent have arisen.
...
PMID:Locoregional Resection in Stage IV breast cancer: tumor biology, molecular and clinical perspectives. 1749 42
Breast metastases from extra-mammary malignancies, especially those mimicking primary inflammatory breast carcinoma, are extremely rare. We report here two cases of inflammatory breast metastases from gastric or ovarian cancer. Both patients, who had prior advanced malignant disease, presented with unilateral breast redness and swelling with
peau d'orange
sign, resembling primary inflammatory breast cancer or acute mastitis. Breast biopsy revealed poorly differentiated adenocarcinoma with signet-ring cells or clear cell carcinoma in the lymphatic vessels and the parenchyma without an in situ lesion, similar to primary lesions of the stomach or ovary, respectively. Immunohistochemical staining for estrogen receptor, progesterone receptor, and gross cystic disease fluid protein 15 was of value for correct diagnosis. Since breast metastasis is a sign of poor prognosis of the primary malignant disease, the possibility of breast metastasis should be considered in appropriate patients to preclude unnecessary major surgery.
Breast Cancer
2008
PMID:Metastatic breast cancer from gastric and ovarian cancer, mimicking inflammatory breast cancer: report of two cases. 1831 79
Massive tumours of the parotid are uncommon as due to their site, they are usually removed at an earlier stage. We present a bizarre case of a carcinoma ex-pleomorphic adenoma which mimicked an advanced
breast cancer
, complete with a 'nipple-like' extension and
peau d'orange
changes in the overlying skin as a result of a dense dermal inflammatory response. A procedure akin to a mastectomy with facial nerve preservation was carried out for removal. To our knowledge,
peau d'orange
has not been reported before in parotid tumours.
...
PMID:Malignant change in a massive pleomorphic adenoma resembling the presentation of advanced inflammatory breast cancer. 2246 57
1
2
Next >>